Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Resource Type
Article
Authors
Jhaveri, K. ; Eli, L.D. ; Wildiers, H. ; Hurvitz, S.A. ; Guerrero-Zotano, A. ; Unni, N. ; Brufsky, A. ; Park, H. ; Waisman, J. ; Yang, E.S. ; Spanggaard, I. ; Reid, S. ; Burkard, M.E. ; Vinayak, S. ; Prat, A. ; Arnedos, M. ; Bidard, F.-C. ; Loi, S. ; Crown, J. ; Bhave, M. ; Piha-Paul, S.A. ; Suga, J.M. ; Chia, S. ; Saura, C. ; Garcia-Saenz, J.Á. ; Gambardella, V. ; de Miguel, M.J. ; Gal-Yam, E.N. ; Raphael, A. ; Stemmer, S.M. ; Ma, C. ; Hanker, A.B. ; Ye, D. ; Goldman, J.W. ; Bose, R. ; Peterson, L. ; Bell, J.S.K. ; Frazier, A. ; DiPrimeo, D. ; Wong, A. ; Arteaga, C.L. ; Solit, D.B.
Source
In Annals of Oncology October 2023 34(10):885-898
Subject
Breast tumor
Language
ISSN
0923-7534